Posted by Michael Wonder on 15 Jun 2017
Kadcyla new deal for breast cancer patients given green light in final draft guidance
15 June 2017 - A new deal on the breast cancer drug Kadcyla (trastuzumab emtansine) means that it can now be recommended for routine funding on the NHS.
Kadcyla is currently being funded through the Cancer Drugs Fund (CDF). The new agreement means if there are no appeals against the new draft guidance, the drug will move out of the CDF into routine NHS funding later this summer. This will mean eligible patients will no longer have to apply for funding and the drug will be paid for in the normal way.
Alongside the offer from Roche to reduce the cost to the NHS, another important factor in the decision to recommend the drug was the committee’s agreement that it was appropriate to compare Kadcyla with Herceptin plus capecitabine. NICE had previously compared Kadcyla’s efficacy against a different combination of treatments.This change was made because Herceptin plus capecitabine is now considered standard treatment for people with advanced breast cancer.
